Outputs (5)

Physiological Role of Vascular Endothelial Growth Factors as Homeostatic Regulators (2018)
Journal Article
Bates, D. O., Beazley-Long, N., Benest, A. V., Ye, X., Ved, N., Hulse, R. P., …Foster, R. R. (2018). Physiological Role of Vascular Endothelial Growth Factors as Homeostatic Regulators. Comprehensive Physiology, 8(3), 955-979. https://doi.org/10.1002/cphy.c170015

The vascular endothelial growth factor (VEGF) family of proteins are key regulators of physiological systems. Originally linked with endothelial function, they have since become understood to be principal regulators of multiple tissues, both through... Read More about Physiological Role of Vascular Endothelial Growth Factors as Homeostatic Regulators.

Regulation of human feto-placental endothelial barrier integrity by vascular endothelial growth factors: competitive interplay between VEGF-A165a, VEGF-A165b, PIGF and VE-cadherin (2017)
Journal Article
Pang, V., Bates, D. O., & Leach, L. (2017). Regulation of human feto-placental endothelial barrier integrity by vascular endothelial growth factors: competitive interplay between VEGF-A165a, VEGF-A165b, PIGF and VE-cadherin. Clinical Science, 131(23), 2763-2775. https://doi.org/10.1042/CS20171252

The human placenta nourishes and protects the developing fetus whilst influencing maternal physiology for fetal advantage. It expresses several members of the VEGF family including the pro-angiogenic/pro-permeability VEGF-A165a isoform, the anti-angi... Read More about Regulation of human feto-placental endothelial barrier integrity by vascular endothelial growth factors: competitive interplay between VEGF-A165a, VEGF-A165b, PIGF and VE-cadherin.

Pharmacology of modulators of alternative splicing (2017)
Journal Article
Bates, D. O., Morris, J. C., Oltean, S., & Donaldson, L. F. (2017). Pharmacology of modulators of alternative splicing. Pharmacological Reviews, 69(1), https://doi.org/10.1124/pr.115.011239

More than 95% of genes in the human genome are alternatively spliced to form multiple transcripts, often encoding proteins with differing or opposing function. The control of alternative splicing is now being elucidated, and with this comes the oppor... Read More about Pharmacology of modulators of alternative splicing.

Vascular endothelial growth factor-A165b is protective and restores endothelial glycocalyx in diabetic nephropathy (2015)
Journal Article

Diabetic nephropathy is the leading cause of ESRD in high-income countries and a growing problem across the world. Vascular endothelial growth factor-A (VEGF-A) is thought to be a critical mediator of vascular dysfunction in diabetic nephropathy, yet... Read More about Vascular endothelial growth factor-A165b is protective and restores endothelial glycocalyx in diabetic nephropathy.

Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia (2014)
Journal Article

Vascular endothelial growth factor-A (VEGF-A) is best known as a key regulator of the formation of new blood vessels. Neutralization of VEGF-A with anti-VEGF therapy e.g. bevacizumab, can be painful, and this is hypothesized to result from a loss of... Read More about Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia.